Please login to the form below

Not currently logged in

FDA approval keeps AZ on track with ambitious Brilinta plans

Receives additional indication for use in heart attack patients

AstraZeneca's resurgent antiplatelet drug Brilinta has scored another FDA approval, getting the go-ahead for longer-term use in heart attack patients.

The FDA priority review approval covers use of the drug beyond the first year in patients who have suffered a prior myocardial infarction (MI) and has been granted on the back of the 21,000-patient PEGASUS study. 

The trial showed Brilinta plus low-dose aspirin was significantly more effective than placebo plus aspirin at reducing the risk of dying from cardiovascular causes, having another heart attack, or having a stroke.

AZ's head of cardiovascular and metabolic disease drug development, Elisabeth Björk, said it is well known that patients remain at risk beyond the first year after their heart attack, adding: "Today's approval is an important milestone that underscores the role BRILINTA can play in reducing the risk of a subsequent cardiovascular event for patients both in the acute setting and in the longer term."

Brilinta was previously approved as 90mg tablet given twice-daily after being shown to be superior to clopidogrel in the PLATO trial, and the new indication gives a green light to a lower 60mg tablet for use as a maintenance dose. The company indicated it would launch the new formulation before the end of the month.

The development is a boost for AZ as it expands the market for Brilinta (ticagrelor) and makes it more likely to meet the company's bullish predictions of $3.5bn in annual sales by 2023, made by chief executive Pascal Soriot while AZ was fending off a takeover attempt from Pfizer. 

The drug still has a long way to go but grew 42% in the first of the year, bringing in $275m and setting it on course for around $600m for 2015 as a whole, although some analysts have expressed scepticism that it can top $2bn at peak.

The maintenance indication is central to AZ's sales predictions for Brilinta as the company believes it could double the number of patients taking the drug. However, it has been suggested the PEGASUS data could also lead to increased prescribing of much cheaper generic clopidogrel, eating into its capacity for expansion.

Article by
Phil Taylor

8th September 2015

From: Sales, Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...